LOUISVILLE, CO — (MARKET WIRE) — October 17, 2006 — GlobeImmune, Inc. announced today that the interim results from a placebo-controlled Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus will be presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on Monday, October 30 in the Late Breaking Poster session. Full abstracts can now be viewed at the AASLD website at https://www.aasld.org.
Presentation Details Poster number: LB17 Location: Exhibit Hall C (Hynes Convention Center) Time: 8:00 am - 5:30 pm Title: "Interim Results from a Randomized, Double-blind, Placebo-controlled Phase 1b Study in Subjects with Chronic HCV after Treatment with GI-5005, a Yeast-Based HCV Immunotherapy Targeting NS3 and Core Proteins." G.T. Everson; M.J. Tong; I.M. Jacobson; D.M. Jensen; A.A. Haller; G.M. Lauer; J. Parker; J. Ferraro; S.E. Cruickshank; R.C. Duke; D. Apelian; T.C. Rodell; E.R. Schiff
About GI-5005
Tarmogens™ (Targeted Molecular Immunogens) are a proprietary, immunotherapeutic platform utilizing whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express disease-specific protein targets. The GI-5005 Tarmogen expresses an NS3-Core fusion protein. These HCV-specific proteins are expressed in infected cells, believed to be essential for viral replication and are highly conserved among HCV genotypes 1a and 1b, the HCV strains most prevalent in the U.S.
GI-5005 is designed to elicit a cellular immune response against cells infected with the HCV virus. The yeast vector is designed not only to stimulate an innate immune response mediated by Toll-like receptors (TLRs), but also to deliver target protein directly to antigen presenting cells, eliciting an antigen-specific helper T cell (CD4) and killer T cells (CD8) cellular immune response to eliminate diseased cells.
About GlobeImmune, Inc.
GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapy products called Tarmogens™ for the treatment of cancer and infectious diseases. The Company’s lead product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection, is currently in a placebo-controlled, Phase 1b human clinical trial. GI-4000, a Tarmogen for the treatment of various Ras-mediated cancers, is in a randomized, placebo-controlled, multi-center Phase 2 trial for the treatment of patients with early-stage pancreas cancer. For additional information, please visit the company’s website at www.globeimmune.com.
This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to the functionality of the Company’s technology. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release. GLOBEIMMUNE CONTACT: Kirk Christoffersen Senior Director, Corporate Development GlobeImmune, Inc. T: 303-625-2700 Email Contact